Actively Recruiting
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Led by Canadian Cancer Trials Group · Updated on 2026-05-12
614
Participants Needed
30
Research Sites
687 weeks
Total Duration
On this page
Sponsors
C
Canadian Cancer Trials Group
Lead Sponsor
M
Melanoma and Skin Cancer Trials Limited
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.
CONDITIONS
Official Title
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Minimum age 18 or as specified in the Product Monograph and eligible for public funding.
- Histologically confirmed melanoma that is unresectable or metastatic (stage III or IV).
- Eligible to receive treatment with a government-approved and publicly funded PD-1 inhibitor.
- Evidence of unresectable or metastatic disease that can be followed, measurable disease not mandatory.
- Patients with stable brain metastases without progression or new/enlarging metastases for at least four weeks, or treated with surgery or stereotactic radiosurgery without progression.
- Able and willing to complete quality of life and health utility questionnaires in English or French.
- Patient consent obtained according to local and regulatory requirements.
- Accessible for treatment and follow-up to document treatment, adverse events, and follow-up.
- Randomized prior to or within 16 weeks of starting PD-1 inhibitor treatment with imaging within 50 days showing no disease progression.
You will not qualify if you...
- Not willing to stop anti-PD-1 therapy if randomized to the intermittent treatment group.
- Contraindications to PD-1 inhibitors as described in the Product Monograph or Provincial Formulary.
- Not eligible to receive anti-PD-1 therapy.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 30 locations
1
Coffs Habour Health Campus - NCCI
Coffs Harbour, New South Wales, Australia, 2450
Actively Recruiting
2
Calvary Mater Newcastle Hospital
Waratah, New South Wales, Australia, 2298
Actively Recruiting
3
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Actively Recruiting
4
Sunshine Coast University Hospital
Birtinya, Queensland, Australia, 4575
Actively Recruiting
5
Cairns Hospital
Cairns, Queensland, Australia, 4870
Actively Recruiting
6
Gold Coast University Hospital
Southport, Queensland, Australia, 4215
Actively Recruiting
7
The Queen Elizabeth Hospital
Woodville, South A., Australia, 5011
Actively Recruiting
8
Monash Medical Centre
Clayton, Victoria, Australia, 3168
Actively Recruiting
9
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Actively Recruiting
10
Mildura Base Public Hospital
Mildura, Victoria, Australia, 3500
Actively Recruiting
11
Royal Brisbane and Womens Hospital
Herston, Australia, 4029
Actively Recruiting
12
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Actively Recruiting
13
BCCA - Surrey
Surrey, British Columbia, Canada, V3V 1Z2
Actively Recruiting
14
BCCA - Vancouver
Vancouver, British Columbia, Canada, V5Z 4E6
Actively Recruiting
15
BCCA - Victoria
Victoria, British Columbia, Canada, V8R 6V5
Actively Recruiting
16
Horizon Health Network
Fredericton, New Brunswick, Canada, E3B 5N5
Actively Recruiting
17
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada, L4M 6M2
Actively Recruiting
18
Health Sciences North
Greater Sudbury, Ontario, Canada, P3E 5J1
Actively Recruiting
19
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
Actively Recruiting
20
Kingston Health Sciences Centre
Kingston, Ontario, Canada, K7L 2V7
Actively Recruiting
21
Waterloo Regional Health Network (WRHN)
Kitchener, Ontario, Canada, N2G 1G3
Actively Recruiting
22
London Health Sciences Centre Research Inc.
London, Ontario, Canada, N6A 5W9
Actively Recruiting
23
Trillium Health Partners - Credit Valley Hospital
Mississauga, Ontario, Canada, L5M 2N1
Actively Recruiting
24
Lakeridge Health Oshawa
Oshawa, Ontario, Canada, L1G 2B9
Actively Recruiting
25
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
26
Odette Cancer Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
27
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
28
The Research Institute of the McGill University
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
29
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada, S4T 7T1
Actively Recruiting
30
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada, S7N 4H4
Actively Recruiting
Research Team
J
Janet Dancey
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here